Español
Nederlands
Italiano
Deutsch
Français
Português
June 14, 2024 has been set as the date when PharmaMar will make the dividend payment, corresponding to 0,65 euros per share.
June 12, 2024 marks the final date to buy shares of PharmaMar if you wish to receive a dividend on June 14, 2024.
PharmaMar (PHM) granted a dividend of 0.65 euros on June 9, 2023.
PharmaMar, which trades under the symbol PHMR, pays dividends to its shareholders every year, although it has been reported that part of its Board of Directors has proposed using this budget item for research and development.
It is a share with a general downward trend, although quite stable and with ample growth possibilities, with a dividend yield of approximately 1.8%, with payments being made once a year between April, May, June or July.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio PharmaMar Dividends
Dividend calendar of PharmaMar
These are the most important events of the PharmaMar calendar in 2024:
| Event | Day |
|---|---|
| Last trading date | June 11, 2024 |
| Ex-Dividend (Ex-Date) | June 12, 2024 |
| Record date | June 13, 2024 |
| Date of payment | June 14, 2024 |
Dividend history of PharmaMar
In this table you can see the complete history:
| Year | Ex-Dividend | Amount | Total |
|---|---|---|---|
| 2023 | 06/07/2023 | 0.65 € | 0.65 € |
| 2022 | 07/13/2022 | 0.65 € | 0.65 € |
| 2021 | 04/28/2021 | 0.6 € | 0.6 € |
| 2020 | 06/26/2020 | 0.480002 € | 0.480002 € |
Information about PharmaMar
PharmaMar is a Spanish company engaged in the pharmaceutical industry, specializing in research, development, creation and marketing of drugs made from marine resources, mainly to treat some types of cancer and mental illnesses such as Alzheimer's disease.
It was founded in 1986, although its beginnings came from Zeltia, which focused on the manufacture of drugs to prevent gynecological, cardiovascular, metabolic and hormonal diseases; it diversified in 1949 when it joined other laboratories and began to produce and package antibiotics, but it was not until 1986 that José María Fernández Sousa established the subsidiary PharmaMar.
Its creation was based on the understanding that most drugs are made from terrestrial components, shrubs, fungi, bacteria, among others.
Its main products include "Yondelis" trabectedin used to treat sarcoma and ovarian cancer, "Zepzelca" lurbinectedin recommended for lung cancer and "Aplidin" plitidepsin recommended for the treatment of multiple myeloma, as well as the commercialization of a rapid diagnostic kit for COVID-19 through its subsidiary Genomica.
Frequently asked questions about PharmaMar dividends
PharmaMar is listed on the Madrid Stock Exchange and is part of the Ibex Medium.
PharmaMar has the Ticker or stock code PHM.
The CEO of PharmaMar in 2024 is Mr. Jose Maria Fernandez Sousa-Faro Ph.D..